Celgene (NASDAQ:CELG)

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Over the past three decades, the unlimited investing potential of biotechnology was all about growth. Companies could grow from nothing to see untold billions of dollars selling cures and treatments ...
Read Full Story »

Short Sellers Make a Move on Big Biotechs

The short interest data are out for the most recent settlement date, July 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Major Biotechs See Rising Tide in Short Interest

The short interest data are out for the most recent settlement date, July 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Why Jounce Therapeutics Popped

Jounce Therapeutics Inc. (NASDAQ: JNCE) shares jumped on Wednesday after the company announced an update on its strategic collaboration with Celgene Corp. (NASDAQ: CELG). This collaboration was originally established in ...
Read Full Story »

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the most recent settlement date, June 28. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Big Biotechs Scare Off Short Sellers

The short interest data are out for the most recent settlement date, June 14. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Big Biotechs Have Short Sellers on the Run

The short interest data are out for the most recent settlement date, May 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Major Biotechs See a Rising Tide in Short Interest

The short interest data are out for the most recent settlement date, May 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Short Sellers Back Off Major Biotechs

The short interest data are out for the most recent settlement date, April 30. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Amex, Bristol-Myers, Celgene, Cognizant, EA, Fortinet, Lyft, Target, Tilray, Walmart and More

Stocks were indicated to open higher after a strong payrolls report on Friday morning. Despite a pullback this week, the markets remain near all-time highs and investors have solid double-digit ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The short interest data are out for the most recent settlement date, April 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

When the stock market is hitting record highs, it's important to remember that it's really a market of stocks rather than a stock market. Not all companies are created equal. ...
Read Full Story »

Big Biotechs Confound Short Sellers

The short interest data are out for the most recent settlement date, March 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

10 Incredibly Surprising Best-Performing S&P 500 Stocks of 2019

The carnage of late 2018 was replaced almost immediately with the return of the big bull market through the entire first quarter of 2019. And with the start of the ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, Celgene, Dow, Fannie Mae, Intel, Lennar, Snap, UGI, Viacom, WEX and More

Stocks were looking for a marginally higher open on Friday, along with a better-than-expected payrolls report from the U.S. Department of Labor. With U.S.-China trade talks reportedly entering their late ...
Read Full Story »